AUTHOR=Stenlid Rasmus , Cerenius Sara Y. , Wen Quan , Aydin Banu Küçükemre , Manell Hannes , Chowdhury Azazul , Kristinsson Hjalti , Ciba Iris , Gjessing Erik S. , Mörwald Katharina , Gomahr Julian , Heu Verena , Weghuber Daniel , Forslund Anders , Bergsten Peter 

TITLE=Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1293093

DOI=10.3389/fendo.2023.1293093

ISSN=1664-2392

ABSTRACT=Background: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT. Subjects and Measurements: This study was a pre-planned sub-study of the Combat-JUDO trial,